Home > Akt & Akt & > Miltefosine

Miltefosine

米替福新,Hexadecylphosphocholine

Miltefosine作用于癌细胞系A431和HeLa，抑制PI3K/Akt活性，ED50分别为17.2 μM和8.1 μM，是第一个用于治疗内脏利什曼病的口服药物，有效对抗前鞭毛体和无鞭毛体。

目录号
EY1191
EY1191
纯度
99.57%
99.57%
规格
100 mg
500 mg
原价
570
1200
售价
570
1200
库存
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Miltefosine inhibits PI3K/Akt activity with ED50 of 17.2 μM and 8.1 μM in carcinoma cell lines A431 and HeLa, first oral drug for Visceral leishmaniasis, effective against both promastigotes and amastigotes.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

    10，20，30，40，， 50μM

  • 动物实验

    50 mg/kgi.p.

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Uberall F, et al. Cancer Res, 1991, 51(3), 807-812.

    分子式
    C21H46NO4P    		 分子量
    407.57    		 CAS号
    58066-85-6    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    <1 mg/mL    		 Water
    80 mg/mL    		 Ethanol
    80 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01462500 Cutaneous Leishmaniasis Drug: Miltefosine Centro Internacional de Entrenamiento e Investigaciones Mdicas|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Phase 4 2011-10-01 2016-08-18
    NCT02687971 Cutaneous Leishmaniasis Drug: Miltefosine Drugs for Neglected Diseases Phase 2 2016-12-01 2017-03-14
    NCT02427308 Leishmaniasis or Other Uses of Miltefosine Drug: Miltefosine Knight Therapeutics (USA) Inc 2015-07-01 2017-02-28
    NCT02193022 Post Kala Azar Dermal Leishmaniasis Drug: Miltefosine International Centre for Diarrhoeal Disease Research, Bangladesh|Thrasher Research Fund Phase 3 2014-07-01 2016-03-24
    NCT02429518 Mucocutaneous Leishmaniasis Drug: Miltefosine Knight Therapeutics (USA) Inc 2015-12-01 2017-02-28
    NCT02431429 Mucocutaneous Leishmaniasis Drug: Miltefosine Knight Therapeutics (USA) Inc 2015-07-01 2017-02-28
    NCT00371995 Visceral Leishmaniasis Drug: Liposomal amphotericin B and Miltefosine Banaras Hindu University|Rajendra Memorial Research Institute of Medical Sciences Phase 2 2007-10-01 2011-06-21
    NCT00487253 Cutaneous Leishmaniasis Drug: Miltefosine|Drug: Meglumine antimoniate Centro Internacional de Entrenamiento e Investigaciones Mdicas|Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnologa (COLCIENCIAS)|INS|Instituto Nacional de Dermatologa Centro dermatolgico Federico Lleras Acosta Phase 3 2007-07-01 2010-02-13
    NCT01380301 Cutaneous Leishmaniasis Drug: Miltefosine and antimony|Drug: Miltefosine alone Foundation Fader|AB Foundation Phase 2 2007-03-01 2011-06-22
    NCT03023111 Cutaneous Leishmaniasis Drug: Sbv|Drug: Miltefosine plus placebo|Drug: Miltefosine plus GM-CSF Hospital Universitrio Professor Edgard Santos|Oswaldo Cruz Foundation Phase 3 2017-03-01 2017-01-18
    NCT02429505 Leishmaniasis Drug: Miltefosine Knight Therapeutics (USA) Inc 2015-07-01 2017-02-28
    NCT01050907 Mucosal Leishmaniasis|Cutaneous Leishmaniasis Drug: miltefosine Knight Therapeutics (USA) Inc Phase 2 2010-05-01 2015-03-24
    NCT02011958 Visceral Leishmaniasis Drug: Liposomal Amphotericin B|Drug: Miltefosine Drugs for Neglected Diseases|Medecins Sans Frontieres, Netherlands|London School of Hygiene and Tropical Medicine|Addis Ababa University|Institute of Tropical Medicine, Belgium|Slotervaart Hospital|University of Gondar Phase 3 2014-07-01 2016-10-06
    NCT00471705 Cutaneous Leishmaniasis Drug: Miltefosine|Device: Thermotherapy|Drug: Glucantime Universidad de Antioquia Phase 3 2006-06-01 2010-07-15
    NCT01377974 Leishmaniasis|Leishmaniasis, Mucocutaneous Drug: Miltefosine|Drug: Standard Treatment Meglumine antimoniate Brasilia University Hospital Phase 2 2009-07-01 2015-06-08
    NCT00600548 Treatment of Cutaneous Leishmaniasis in Brazil. Drug: Miltefosine.|Drug: Meglumine antimoniate.|Drug: Miltefosine.|Drug: Meglumine antimoniate. Hospital Universitrio Professor Edgard Santos|Conselho Nacional de Desenvolvimento Cientfico e Tecnolgico|Ministerio de Ciencia e Innovacin, Spain|Ministrio da Sade|AEterna Zentaris Phase 2 2007-07-01 2010-04-14
    NCT00373568 Leishmaniasis Drug: miltefosine: 2.5 mg/kg/day for 42 days AB Foundation Phase 1|Phase 2 2005-04-01 2010-05-29
    NCT02431143 Visceral Leishmaniasis Drug: Miltefosine Drugs for Neglected Diseases Phase 2 2015-05-01 2016-10-10
    NCT02530697 Leishmaniasis Drug: Meglumine antimoniate|Drug: Miltefosine|Drug: Pentoxifylline University of Brasilia Phase 2 2015-08-01 2016-05-22
    NCT01380314 Cutaneous Leishmaniasis Drug: Miltefosine + Imiquimod|Drug: Miltefosine 150 mg x day + Placebo Foundation Fader Phase 2 2008-03-01 2011-06-22
    NCT01122771 Visceral Leishmaniasis Drug: Liposomal amphotericin B|Drug: liposomal amphotericin B + miltefosine|Drug: liposomal amphotericin B + paromomycin|Drug: Miltefosine + Paromomycin Drugs for Neglected Diseases|Shaheed Surhawardy Medical College and Hospital|International Centre for Diarrhoeal Disease Research, Bangladesh Phase 3 2010-05-01 2016-01-20

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：